Hyperparathyroidism | The Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study
Hyperparathyroidism research study
What is the primary objective of this study?
This study will evaluate whether commonly used blood pressure medications called \"ACE inhibitors\" can lower parathyroid hormone.
Who is eligible to participate?
Inclusion Criteria: - Healthy subjects with with no medical problems (n=15) and individuals with primary hyperparathyroidism (n=30) - normal blood pressure or stage 1 hypertension that is either untreated, or adequately treated with a single anti-hypertensive medication. - Age >18 years and <80 years - Estimated GFR > 60ml/min Exclusion Criteria: - Chronic Kidney Disease or eGFR<60 - Stage 2 or Stage 3 hypertension or the use of more than 1 antihypertensive drug - Type 2 Diabetes Mellitus that is not controlled by diet or Metformin alone or with a Hemoglobin A1c >7.5% - History of liver failure - History of heart failure - The use of typical or atypical antipsychotic medications or lithium. - Chronic inflammatory conditions (such as inflammatory bowel disease or arthritis) that are treated with prescribed doses of NSAIDs or glucocorticoids - The use of prescribed doses of potassium supplements. - Illness requiring overnight hospitalization in the past 6 months - Active tobacco or recreational drug use - Pregnancy or current breast feeding
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Drug:LisinoprilEach subject will receive one week of lisinopril and return for repeat for blood measurements.
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
lisinoprilLisinopril - open-label, 2.5-40mg daily
Start Date: October 2012
Completed Date: December 2016
Primary Outcome: Parathyroid Hormone Following 1 Week of ACE Inhibitor Administration
Secondary Outcome: Urinary Aldosterone Excretion Measurements Following 1 Week of ACE Inhibitor Therapy
Study sponsors, principal investigator, and references
Principal Investigator: Anand Vaidya, MD, MMSc
Lead Sponsor: Brigham and Women's Hospital